ES2084621T3 - Proteina biologicamente activa modificada. - Google Patents

Proteina biologicamente activa modificada.

Info

Publication number
ES2084621T3
ES2084621T3 ES90112690T ES90112690T ES2084621T3 ES 2084621 T3 ES2084621 T3 ES 2084621T3 ES 90112690 T ES90112690 T ES 90112690T ES 90112690 T ES90112690 T ES 90112690T ES 2084621 T3 ES2084621 T3 ES 2084621T3
Authority
ES
Spain
Prior art keywords
biologically active
modified protein
active modified
active protein
consisting essentially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90112690T
Other languages
English (en)
Inventor
Yutaka Mizushima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP1310056A external-priority patent/JP2679852B2/ja
Application filed by Asahi Glass Co Ltd, Seikagaku Corp filed Critical Asahi Glass Co Ltd
Application granted granted Critical
Publication of ES2084621T3 publication Critical patent/ES2084621T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UNA PROTEINA MODIFICADA, BIOLOGICAMENTE ACTIVA, QUE SE COMPONE ESENCIALMENTE DE UNA PROTEINA BIOLOGICAMENTE ACTIVA ENLAZADA CON LECITINA MEDIANTE UN FIJADOR QUIMICO.
ES90112690T 1989-07-06 1990-07-03 Proteina biologicamente activa modificada. Expired - Lifetime ES2084621T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17437189 1989-07-06
JP1310056A JP2679852B2 (ja) 1989-11-29 1989-11-29 経口及び局所投与用生物活性蛋白組成物

Publications (1)

Publication Number Publication Date
ES2084621T3 true ES2084621T3 (es) 1996-05-16

Family

ID=26496004

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90112690T Expired - Lifetime ES2084621T3 (es) 1989-07-06 1990-07-03 Proteina biologicamente activa modificada.

Country Status (8)

Country Link
US (3) US5109118A (es)
EP (1) EP0406804B1 (es)
AT (1) ATE133200T1 (es)
AU (1) AU647027B2 (es)
CA (1) CA2020439C (es)
DE (1) DE69024862T2 (es)
DK (1) DK0406804T3 (es)
ES (1) ES2084621T3 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
WO1995007089A1 (en) 1993-09-09 1995-03-16 Imutec Corporation Immunomodulating compositions from bile
JPH08208511A (ja) * 1995-01-31 1996-08-13 Samu Kenkyusho:Kk 抗運動ニューロン疾患剤
AU711294B2 (en) 1995-03-16 1999-10-07 Erin Mills Biotech Inc. Immunomodulating compositions from bile for the treatment of immune system disorders
EP0790060B1 (en) * 1995-09-06 2003-11-12 Kyowa Hakko Kogyo Co., Ltd. Substance ameliorant le metabolisme des graisses
US20040101569A1 (en) * 1996-05-16 2004-05-27 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
AU2001234178A1 (en) * 2000-02-29 2001-09-12 Ltt Institute Co., Ltd. Modified bdnf
EP1627885B8 (en) * 2003-04-30 2015-02-18 Innovative Medicine and Any Peptide Pharmaceuticals Corp Polypeptide capable of assisting digestive organ absorption
CN100516208C (zh) * 2004-10-12 2009-07-22 日本株式会社Ltt生物医药 卵磷脂化超氧化物歧化酶组合物及其制备方法
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
KR100752990B1 (ko) * 2006-08-02 2007-08-30 주식회사 대웅 나노리포좀 및 천연 추출물을 포함하는 피부 질환의 예방또는 치료용 조성물
CA2739936C (en) 2008-10-17 2017-12-12 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
CA2773340C (en) 2009-09-08 2019-07-23 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
ES2710617T3 (es) 2010-04-21 2019-04-26 Signature Therapeutics Inc Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
WO2011133178A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
AU2012205733B2 (en) 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
US8685916B2 (en) 2011-03-09 2014-04-01 Signature Therapeutics, Inc. Opioid prodrugs with heterocyclic linkers
WO2012122422A2 (en) 2011-03-09 2012-09-13 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0122151B1 (en) * 1983-04-11 1989-02-15 Meito Sangyo Kabushiki Kaisha Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique
US4560599A (en) * 1984-02-13 1985-12-24 Marquette University Assembling multilayers of polymerizable surfactant on a surface of a solid material
US4957740A (en) * 1984-10-31 1990-09-18 Centerchem, Inc. Composition for preventing or alleviating skin irritation by formulations containing superoxide dismutase
EP0211042A1 (en) * 1985-01-18 1987-02-25 Cooper-Lipotech, Inc. Liposome composition and method
JPS63135395A (ja) * 1986-11-28 1988-06-07 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
JPS63253031A (ja) * 1987-04-09 1988-10-20 Yutaka Mizushima ス−パ−オキサイドジスムタ−ゼ結合リピツドマイクロスフエア−および該リピツドマイクロスフエア−を含有する脂肪乳剤
IE64284B1 (en) * 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
US5080833A (en) * 1987-09-21 1992-01-14 Kabushiki Kaisha Toshiba Immobilization of bioactive substance on lipid composition containing modified lipid compound
JPH01235593A (ja) * 1988-03-15 1989-09-20 Fuji Photo Film Co Ltd 機能性有機薄膜
JPH04504258A (ja) * 1989-03-29 1992-07-30 アルコン　ラボラトリーズ　インコーポレイテッド モノアシルホスホグリセリド類を使用して眼薬の角膜への浸透を増強する方法
DE3919982A1 (de) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform

Also Published As

Publication number Publication date
EP0406804A2 (en) 1991-01-09
ATE133200T1 (de) 1996-02-15
CA2020439A1 (en) 1991-01-07
AU647027B2 (en) 1994-03-17
DE69024862D1 (de) 1996-02-29
EP0406804B1 (en) 1996-01-17
US5362491A (en) 1994-11-08
US5310958A (en) 1994-05-10
DE69024862T2 (de) 1996-09-05
DK0406804T3 (da) 1996-06-10
US5109118A (en) 1992-04-28
EP0406804A3 (en) 1992-04-01
CA2020439C (en) 1998-11-24
AU5865290A (en) 1991-01-10

Similar Documents

Publication Publication Date Title
ES2084621T3 (es) Proteina biologicamente activa modificada.
ES2132066T3 (es) Procedimiento para la produccion de proteina biologicamente activa (v.g. tfg).
DE3586313T2 (de) Konjugate von pharmazeutisch nuetzlichen proteinen.
SE8000470L (sv) Vevnadsbindmedel och forfarande for dess framstellning samt bindmedlets anvendning
FI91160B (fi) Menetelmä modifioidun ihmisen t-PA-proteiinin valmistamiseksi
ES2043609T3 (es) Composiciones de interleucina-2.
DK538286A (da) Humanlysozym
FI904852A0 (fi) Antikoagulantpeptider.
ES536059A0 (es) Procedimiento de ligacion de sustancias biologicamente importantes
DK109590A (da) Biologisk aktivt protein
PT90504A (pt) Processo para a preparacao de alcoois peptidicos com actividade anticoagulante
DK614489A (da) Peptidderivater
DK191089D0 (da) Biologisk aktive forbindelser
GR890100246A (el) Εναντιοισομερη η χειραλικα σουλφοξειδια.
DE3869939D1 (de) Biologisch wirksame peptide.
DE3782199T2 (de) Biologisch aktive peptide tan-866.
KR890016134U (ko) 신발제조용 인조피혁
PT7986Y (pt) Fixacao de protese capilar por integracao com ponto natural
KR880021166U (ko) 1회용 슬리퍼
KR880017238U (ko) 신발깔창 부착용 공기주입기

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 406804

Country of ref document: ES